These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 33654204)

  • 1. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.
    Larson RA; Mandrekar SJ; Huebner LJ; Sanford BL; Laumann K; Geyer S; Bloomfield CD; Thiede C; Prior TW; Döhner K; Marcucci G; Voso MT; Klisovic RB; Galinsky I; Wei AH; Sierra J; Sanz MA; Brandwein JM; de Witte T; Niederwieser D; Appelbaum FR; Medeiros BC; Tallman MS; Krauter J; Schlenk RF; Ganser A; Serve H; Ehninger G; Amadori S; Gathmann I; Döhner H; Stone RM
    Leukemia; 2021 Sep; 35(9):2539-2551. PubMed ID: 33654204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
    Stone RM; Mandrekar SJ; Sanford BL; Laumann K; Geyer S; Bloomfield CD; Thiede C; Prior TW; Döhner K; Marcucci G; Lo-Coco F; Klisovic RB; Wei A; Sierra J; Sanz MA; Brandwein JM; de Witte T; Niederwieser D; Appelbaum FR; Medeiros BC; Tallman MS; Krauter J; Schlenk RF; Ganser A; Serve H; Ehninger G; Amadori S; Larson RA; Döhner H
    N Engl J Med; 2017 Aug; 377(5):454-464. PubMed ID: 28644114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
    Kim M; Williams S
    Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
    Stansfield LC; Pollyea DA
    Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.
    Stone RM; Fischer T; Paquette R; Schiller G; Schiffer CA; Ehninger G; Cortes J; Kantarjian HM; DeAngelo DJ; Huntsman-Labed A; Dutreix C; del Corral A; Giles F
    Leukemia; 2012 Sep; 26(9):2061-8. PubMed ID: 22627678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.
    Voso MT; Larson RA; Jones D; Marcucci G; Prior T; Krauter J; Heuser M; Lavorgna S; Nomdedeu J; Geyer SM; Walker A; Wei AH; Sierra J; Sanz MA; Brandwein JM; de Witte TM; Jansen JH; Niederwieser D; Appelbaum FR; Medeiros BC; Tallman MS; Schlenk RF; Ganser A; Amadori S; Cheng Y; Chen Y; Pallaud C; Du L; Piciocchi A; Ehninger G; Byrd J; Thiede C; Döhner K; Stone RM; Döhner H; Bloomfield CD; Lo-Coco F
    Blood Adv; 2020 Oct; 4(19):4945-4954. PubMed ID: 33049054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States.
    Stein E; Xie J; Duchesneau E; Bhattacharyya S; Vudumula U; Ndife B; Bonifacio G; Guerin A; Li N; Joseph G
    Pharmacoeconomics; 2019 Feb; 37(2):239-253. PubMed ID: 30382485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients.
    Cooper BW; Kindwall-Keller TL; Craig MD; Creger RJ; Hamadani M; Tse WW; Lazarus HM
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):428-432.e2. PubMed ID: 25776192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
    Fischer T; Stone RM; Deangelo DJ; Galinsky I; Estey E; Lanza C; Fox E; Ehninger G; Feldman EJ; Schiller GJ; Klimek VM; Nimer SD; Gilliland DG; Dutreix C; Huntsman-Labed A; Virkus J; Giles FJ
    J Clin Oncol; 2010 Oct; 28(28):4339-45. PubMed ID: 20733134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.
    Schmalbrock LK; Dolnik A; Cocciardi S; Sträng E; Theis F; Jahn N; Panina E; Blätte TJ; Herzig J; Skambraks S; Rücker FG; Gaidzik VI; Paschka P; Fiedler W; Salih HR; Wulf G; Schroeder T; Lübbert M; Schlenk RF; Thol F; Heuser M; Larson RA; Ganser A; Stunnenberg HG; Minucci S; Stone RM; Bloomfield CD; Döhner H; Döhner K; Bullinger L
    Blood; 2021 Jun; 137(22):3093-3104. PubMed ID: 33598693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.
    Tzogani K; Yu Y; Meulendijks D; Herberts C; Hennik P; Verheijen R; Wangen T; Dahlseng Håkonsen G; Kaasboll T; Dalhus M; Bolstad B; Salmonson T; Gisselbrecht C; Pignatti F
    ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.
    Döhner H; Weber D; Krzykalla J; Fiedler W; Wulf G; Salih H; Lübbert M; Kühn MWM; Schroeder T; Salwender H; Götze K; Westermann J; Fransecky L; Mayer K; Hertenstein B; Ringhoffer M; Tischler HJ; Machherndl-Spandl S; Schrade A; Paschka P; Gaidzik VI; Theis F; Thol F; Heuser M; Schlenk RF; Bullinger L; Saadati M; Benner A; Larson R; Stone R; Döhner K; Ganser A
    Blood Adv; 2022 Sep; 6(18):5345-5355. PubMed ID: 35486475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia.
    Maziarz RT; Levis M; Patnaik MM; Scott BL; Mohan SR; Deol A; Rowley SD; Kim DDH; Hernandez D; Rajkhowa T; Haines K; Bonifacio G; Rine P; Purkayastha D; Fernandez HF
    Bone Marrow Transplant; 2021 May; 56(5):1180-1189. PubMed ID: 33288862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Midostaurin in FLT3-mutated acute myeloid leukaemia.
    Das M
    Lancet Oncol; 2017 Aug; 18(8):e439. PubMed ID: 28669736
    [No Abstract]   [Full Text] [Related]  

  • 16. Updated safety of midostaurin plus chemotherapy in newly diagnosed
    Roboz GJ; Strickland SA; Litzow MR; Dalovisio A; Perl AE; Bonifacio G; Haines K; Barbera A; Purkayastha D; Sweet K
    Leuk Lymphoma; 2020 Dec; 61(13):3146-3153. PubMed ID: 32812818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Midostaurin for the treatment of acute myeloid leukemia.
    Patnaik MM
    Future Oncol; 2017 Sep; 13(21):1853-1871. PubMed ID: 28610444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Midostaurin + Chemo Ups AML Survival.
    Cancer Discov; 2016 Feb; 6(2):OF2. PubMed ID: 26739883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center.
    Willis C; Menon J; Unni S; Au T; Yoo M; Biskupiak J; Brixner D; Ndife B; Joseph G; Bonifacio G; Stein E; Tantravahi S; Shami PJ; Kovacsovics T; Stenehjem D
    Leuk Res; 2019 Dec; 87():106262. PubMed ID: 31756575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Midostaurin approved for FLT3-mutated AML.
    Levis M
    Blood; 2017 Jun; 129(26):3403-3406. PubMed ID: 28546144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.